ACTH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
=== In the United States of America === Clinical pathologists work in close collaboration with clinical scientists (clinical biochemists, clinical microbiologists, etc.), medical technologists, hospital administrators, and referring physicians to ensure the accuracy and optimal utilization of laboratory testing. Clinical pathology is one of the two major divisions of pathology, the other being anatomical pathology. Often, pathologists practice both anatomical and clinical pathology, a combination sometimes known as general pathology. Similar specialties exist in veterinary pathology. Clinical pathology is itself divided into subspecialties, the main ones being clinical chemistry, clinical hematology/blood banking, hematopathology and clinical microbiology and emerging subspecialties such as molecular diagnostics and proteomics. Many areas of clinical pathology overlap with anatomic pathology. Both can serve as medical directors of CLIA certified laboratories. Under the CLIA law, only the US Department of Health and Human Services approved Board Certified Ph.D., DSc, or MD and DO can perform the duties of a Medical or Clinical Laboratory Director. This overlap includes immunoassays, flow cytometry, microbiology and cytogenetics and any assay done on tissue. Overlap between anatomic and clinical pathology is expanding to molecular diagnostics and proteomics as we move towards making the best use of new technologies for personalized medicine.
The use of N-terminal Fmoc deprotection scheme is truly orthogonal under SPPS conditions. Fmoc deprotection is a base-catalyzed elimination reaction that typically uses 20–50% piperidine in DMF. The revealed alpha-amine functionality is therefore neutral, and consequently no neutralization of the peptide-resin is required, as in the case of the Boc/Bzl approach. The lack of electrostatic repulsion between the peptide chains can lead to increased risk of aggregation with Fmoc/tBu SPPS however. Because the liberated fluorenyl group is a chromophore, Fmoc deprotection can be monitored by UV absorbance of the reaction mixture, a strategy which is employed in automated peptide synthesizers. The ability of the Fmoc group to be cleaved under relatively mild basic conditions while being stable to acid allows the use of side chain protecting groups such as Boc and tBu that can be removed in milder acidic final cleavage conditions (TFA) than those used for final cleavage in Boc/Bzl SPPS (HF). Scavengers such as water and triisopropylsilane (TIPS) are most commonly added during the final cleavage in order to prevent side reactions with reactive cationic species released as a result of side chain deprotection. Nevertheless, many other scavenger compounds could be used as well. The resulting crude peptide is obtained as a TFA salt, which is potentially more difficult to solubilize than the fluoride salts generated in Boc SPPS. Fmoc/tBu SPPS is less atom-economical, as the fluorenyl group has a much higher mass than the Boc group.
=== Pharmacogenetics === Since doxepin is mainly metabolized by CYP2D6, CYP2C9, and CYP2C19, genetic variations within the genes coding for these enzymes can affect its metabolism, leading to changes in the concentrations of the drug in the body. Increased concentrations of doxepin may increase the risk for side effects, including anticholinergic and nervous system adverse effects, while decreased concentrations may reduce the drug's efficacy. Individuals can be categorized into different types of cytochrome P450 metabolizers depending on which genetic variations they carry. These metabolizer types include poor, intermediate, extensive, and ultrarapid metabolizers. Most people are extensive metabolizers, and have "normal" metabolism of doxepin. Poor and intermediate metabolizers have reduced metabolism of the drug as compared to extensive metabolizers; patients with these metabolizer types may have an increased probability of experiencing side effects. Ultrarapid metabolizers break down doxepin much faster than extensive metabolizers; patients with this metabolizer type may have a greater chance of experiencing pharmacological failure. A study assessed the metabolism of a single 75 mg oral dose of doxepin in healthy volunteers with genetic polymorphisms in CYP2D6, CYP2C9, and CYP2C19 enzymes. In CYP2D6 extensive, intermediate, and poor metabolizers, the mean clearance rates of (E)-doxepin were 406, 247, and 127 L/hour, respectively (~3-fold difference between extensive and poor).
Due to his high popularity, Duterte remained influential before the national elections as several presidential candidates were open to his endorsement. As the Cusi faction was left without a standard bearer following Go's withdrawal, allies of Duterte endorsed different candidates. The Cusi faction eventually endorsed presidential candidate Marcos and some officials called for Duterte to do the same. Stressing he would remain neutral, Duterte refused to heed their calls and insisted on endorsing only Sara as vice president and 17 senatorial candidates. Additionally, in an effort to protect their integrity, Duterte barred his Cabinet members from campaigning for any candidate. Despite non-endorsement, Duterte hinted on the next president's preferred qualities: decisive, compassionate, a good judge of a person, and preferably, a lawyer; this led a PDP-Laban official to believe Duterte gave a "virtual endorsement" for Vice President Leni Robredo, who was Marcos' chief rival in the presidential race. In March 2022, Go said Duterte briefly met with Marcos and gave him advice on the presidency, but could not say whether Duterte gave Marcos an endorsement.
Sources: en.wikipedia.org
==== Longnose gar ==== Due to the heavily scaled skin of the Longnose gar, some of the mechanical properties differ from model of describing how eel skin adds movement. The scale row resists longitudinal forces, which unlike eel skin, makes the skin stiffer in the longitudinal direction, providing myomeres with leverage and anchorage for pulling tendons. At low curvatures, it appears that the dermis is slack on both the concave and convex sides of the body. When the dermis is placed in tension, and resistance to bending is developed, which is referred to as flexural stiffness of the fish skin. The flexural stiffness is a result of the two dimensional stiffness of fish with heavily scaled skin, such as the longnose gar. This mechanical property of fish skin is important to the way a fish swims, because this mechanical property passively stiffens the body, which would otherwise would have been done muscularly. The flexural stiffness of fish skin act in a manner similar to the mechanism by which eel skin acts as an external tendon, however in the case of fish skin, the flexural stiffness acts as a mechanism to decelerate body movement rather than to generate a propulsive force.
== Growth and morphology == The conidia of A. parasiticus have rough, thick walls, are spherical in shape, have short conidiophores (~400 μm) with small vesicles averaging 30 μm in size to which the phialides are directly attached. A. parasiticus is further distinguished by its dark green colony colour. Aspergillus parasiticus colonies are dark green. The average growth temperature for this fungus ranges between 12 and 42 °C with the optimum temperature for growth is at 32 °C and no growth reported at 5 °C. Growth pH ranges from 2.4 to 10.5 with the optimum growth ranging between 3.5–8. For the best growth of the fungus the carbon and nitrogen content in the soil is 1:1 and the pH 5.5. A. parasiticus normally reproduces asexually however, the presence of single mating genes MAT1-1 or MAT1-2 in different strains of the fungus suggests it has a heterothallic mating system and may have a hitherto unrecognized teleomorph. A. parasiticus grows on cereal agar, Czapek agar, malt extract agar, malt salt agar, and potato dextrose agar. The sclerotia and stromata transform from white to pink, dark brown and black. When grown on "Aspergillus flavus and parasiticus" agar (AFPA), colonies show an orange yellow reverse colouration. The conidia are pink when grown on media containing anisaldehyde. A. parasiticus has been cultivated on both Czapek yeast extract agar (CYA) plates and Malt Extract Agar Oxoid (MEAOX) plates. The growth morphology of the colonies can be seen in the pictures below.
=== Glycine === Glycine is biosynthesized from serine, catalyzed by serine hydroxymethyltransferase (SHMT). The enzyme effectively replaces a hydroxymethyl group with a hydrogen atom. SHMT is coded by the gene glyA. The regulation of glyA is complex and is known to incorporate serine, glycine, methionine, purines, thymine, and folates, The full mechanism has yet to be elucidated. The methionine gene product MetR and the methionine intermediate homocysteine are known to positively regulate glyA. Homocysteine is a coactivator of glyA and must act in concert with MetR. On the other hand, PurR, a protein which plays a role in purine synthesis and S-adeno-sylmethionine are known to down regulate glyA. PurR binds directly to the control region of glyA and effectively turns the gene off so that glycine will not be produced by the bacterium.
, where e is the engineering normal strain, L is the original length of the fiber and l is the final length of the fiber. The true shear strain is defined as the change in the angle (in radians) between two material line elements initially perpendicular to each other in the undeformed or initial configuration. The engineering shear strain is defined as the tangent of that angle, and is equal to the length of deformation at its maximum divided by the perpendicular length in the plane of force application, which sometimes makes it easier to calculate.
Information about the maximum size of the clown loach varies, with some estimates ranging up to 20–30 cm (7.9–11.8 in), and with typical adult sizes ranging from 15–20 cm (5.9–7.9 in). The fish's body is long and laterally compressed, with an arched dorsal surface and a flat ventral surface. Its head is relatively large and its mouth faces downward with thick, fleshy lips, and four pairs of barbels. The barbels on the lower jaw are small and difficult to see. Clown loaches can make clicking sounds when they are happy, being territorial (used as a type of weapon/warning) or mating. This sound is produced by the grinding of their pharyngeal teeth. The body is whitish-orange to reddish-orange, with three thick, black, triangular, vertical bands. The anterior band runs from the top of the head and through the eye, the medial band lies between the head and the dorsal fin, and wraps around to the ventral surface, and the posterior band covers almost all of the caudal peduncle and extends to the anal fin. There is some regional colour variation within the species; the pelvic fins on fish from Borneo are reddish-orange and black, while the pelvic fins on fish from Sumatra are entirely reddish-orange. The fish is sexually dimorphic, with females being slightly plumper than males. In addition, the tips of the tail on the male curve inwards slightly, whereas the females have straight tips. The fish has a movable spine that lies in a groove below the eye, which may be extended as a defence mechanism. The spine may cause a painful wound, but is not venomous.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.